Enamine, EMBL Partner on Cancer Drug Discovery Research

News   Apr 25, 2017 | Original story from Enamine

 
Enamine, EMBL Partner on Cancer Drug Discovery Research
 
 
 

RELATED ARTICLES

CRISPR Screening Reveals Sickle Cell Disease Target

News

A key signaling protein, known as heme-regulated inhibitor (HRI), has been identified as a potential therapeutic target for the development of drugs to treat sickle cell disease, using a CRISPR screening approach.

READ MORE

UCL Technology Fund Investment MeiraGTx Raises $75 Million in IPO

News

MeiraGTx Holdings plc raised $75 million of gross proceeds upon close of the company’s initial public offering (IPO).

READ MORE

A Carcinogen at the Gym

News

Gyms are places people go to get healthier. But nearly half the gyms in the U.S. contain a potentially addictive carcinogen - tanning beds, report UConn researchers.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Biopharma Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE
 

We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy